Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2012

View Archived Issues

Catabasis Pharmaceuticals synthesizes novel inhibitors of NF-kappaB signaling

Fred Hutchinson and GSK partner to develop muscular dystrophy therapeutics

Stemline Therapeutics describes MAb conjugate against IL-3R-alpha

PDC Biotech completes phase I trial of PDC-13 in primary dysmenorrhea

Sucampo receives milestone payment for first sale of Amitiza in Japan

Anacor discloses results from phase II trial of AN-2728

Pharmascience regains global rights to IAP inhibitor oncology program

Phase IIb study commences for inhaled LAMA candidate for the treatment of COPD

Interim data from phase I study of IPH-2101 plus lenalidomide reported

Durata Therapeutics reports phase III data for dalbavancin

uniQure begins phase I study in acute intermittent porphyria

KaloBios Pharmaceuticals KB-003 for chronic myelomonocytic leukemia

New phase IIb study of Zorcell psoriasis vaccine begins

Medicago receives support for influenza vaccine programs

Dosing begins in CUPID trial of Mydicar in advanced heart failure

Researchers design potent domain antibody inhibitors of amyloid formation

TiGenix presents novel immunomodulatory cells for MS

New fusion proteins disclosed by the National Institute of Immunology

Researchers at Bristol-Myers Squibb synthesize new HCV NS5A inhibitors

FORMA Therapeutics patents new NAmPRTase inhibitors

Eli Lilly shifts focus of phase III solanezumab trials

Vernalis' study of V-81444 confirms dose for proof-of-concept trial

Boehringer Ingelheim discontinues phase II dabigatran etexilate trial

Novel GR antagonists discovered to prevent antipsychotic-induced weight gain

NADPH oxidase 4 identified as therapeutic target in asthma

New product for congenital factor XIII deficiency launched

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...